40 related articles for article (PubMed ID: 1696869)
1. Human immunodeficiency virus 1: predominance of a group-specific neutralizing epitope that persists despite genetic variation.
Dis Markers; 1990; 8(2):105-7. PubMed ID: 1696869
[No Abstract] [Full Text] [Related]
2. Neutralization of human immunodeficiency virus type 1 (HIV-1) mediated by parotid IgA of HIV-1-infected patients.
Moja P; Tranchat C; Tchou I; Pozzetto B; Lucht F; Desgranges C; Genin C
J Infect Dis; 2000 May; 181(5):1607-13. PubMed ID: 10823760
[TBL] [Abstract][Full Text] [Related]
3. Human immunodeficiency virus 1. Predominance of a group-specific neutralizing epitope that persists despite genetic variation.
Berkower I; Smith GE; Giri C; Murphy D
J Exp Med; 1989 Nov; 170(5):1681-95. PubMed ID: 2478654
[TBL] [Abstract][Full Text] [Related]
4. Effect of epitope position on neutralization by anti-human immunodeficiency virus monoclonal antibody 2F5.
Ou W; Lu N; Yu SS; Silver J
J Virol; 2006 Mar; 80(5):2539-47. PubMed ID: 16474160
[TBL] [Abstract][Full Text] [Related]
5. Epitopes corresponding to the envelope genetic subtype are present on the surface of free virions of HIV-1 group M primary isolates and can be detected in neutralization assays with extended incubation phases.
Davis D; Donners H; Willems B; Vermoesen T; Heyndrickx L; Colebunders R; van der Groen G
J Med Virol; 2003 Nov; 71(3):332-42. PubMed ID: 12966537
[TBL] [Abstract][Full Text] [Related]
6. Neutralization of human immunodeficiency virus type 1 (HIV-1) with antibody from carriers' plasma against HIV-1 protein p17.
Kageyama S; Katsumoto T; Taniguchi K; Ismail SI; Shimmen T; Sasao F; Gao M; Owatari S; Wakamiya N; Tsuchie H; Ueda S; Shiraki K; Kurimura T
Acta Virol; 1996 Sep; 40(4):195-200. PubMed ID: 9014009
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing antibodies in relation to antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus type I.
Böttiger B; Ljunggren K; Karlsson A; Krohn K; Fenyö EM; Jondal M; Biberfeld G
Clin Exp Immunol; 1988 Sep; 73(3):339-42. PubMed ID: 3208445
[TBL] [Abstract][Full Text] [Related]
8. Inter-subtype cross-neutralizing antibodies recognize epitopes on cell-associated HIV-1 virions.
Donners H; Davis D; Willems B; van der Groen G
J Med Virol; 2003 Feb; 69(2):173-81. PubMed ID: 12683404
[TBL] [Abstract][Full Text] [Related]
9. Peptide mimicry of carbohydrate epitopes on human immunodeficiency virus.
Agadjanyan M; Luo P; Westerink MA; Carey LA; Hutchins W; Steplewski Z; Weiner DB; Kieber-Emmons T
Nat Biotechnol; 1997 Jun; 15(6):547-51. PubMed ID: 9181577
[TBL] [Abstract][Full Text] [Related]
10. Common epitope in human immunodeficiency virus (HIV) I-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV I infected individuals.
Dis Markers; 1990; 8(3):165-6. PubMed ID: 1703062
[No Abstract] [Full Text] [Related]
11. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
12. [Neutralizing antibodies to 5 HIV-1 strains in macaques immunized with the multi-epitope polypeptide TAB9].
Navea Leyva LM; Lobaina Bartelemy L; Dubed Echevarría M; Alvarez Seguí G; Gómez Rodríguez C; Duarte Cano C
Rev Cubana Med Trop; 2000; 52(2):115-8. PubMed ID: 11107905
[TBL] [Abstract][Full Text] [Related]
13. Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response.
Cleveland SM; Buratti E; Jones TD; North P; Baralle F; McLain L; McInerney T; Durrani Z; Dimmock NJ
Virology; 2000 Jan; 266(1):66-78. PubMed ID: 10612661
[TBL] [Abstract][Full Text] [Related]
14. Neutralizing epitopes in the membrane-proximal region of HIV-1 gp41: genetic variability and co-variation.
Dong XN; Chen YH
Immunol Lett; 2006 Aug; 106(2):180-6. PubMed ID: 16859756
[TBL] [Abstract][Full Text] [Related]
15. Preparation and characterization of human HIV type 1 neutralizing reference sera.
Vujcic LK; Quinnan GV
AIDS Res Hum Retroviruses; 1995 Jul; 11(7):783-7. PubMed ID: 7546904
[TBL] [Abstract][Full Text] [Related]
16. Neutralization of HIV infection by serum IgA antibodies.
Kozlowski P; Buckheit RW; Jackson S
Adv Exp Med Biol; 1995; 371B():1027-30. PubMed ID: 7502745
[No Abstract] [Full Text] [Related]
17. Unscreened transfusion related human immunodeficiency virus type-I infection amongst Indian thalassemic children.
Kumar RM; Rizk DE; Khuranna AK
Am J Hematol; 1996 Sep; 53(1):51-2. PubMed ID: 8813103
[No Abstract] [Full Text] [Related]
18. [3 cases of viral carriage detected during screening for HIV antibodies].
Shelukhina EM; Chekunova EV; Matsevich GR; Okunev IA; Marennikova SS; Zak MR
Zh Mikrobiol Epidemiol Immunobiol; 1991 Mar; (3):16-8. PubMed ID: 1872091
[TBL] [Abstract][Full Text] [Related]
19. Development of HIV-1 group-specific neutralizing antibodies after seroconversion.
McKnight A; Clapham PR; Goudsmit J; Cheingsong-Popov R; Weber JN; Weiss RA
AIDS; 1992 Aug; 6(8):799-802. PubMed ID: 1418776
[TBL] [Abstract][Full Text] [Related]
20. The cat and mouse of HIV-1 antibody escape.
Mascola JR
PLoS Pathog; 2009 Sep; 5(9):e1000592. PubMed ID: 19763273
[No Abstract] [Full Text] [Related]
[Next] [New Search]
